Aquestive Therapeutics (NASDAQ:AQST) Releases Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Aquestive Therapeutics (NASDAQ:AQST) posted its quarterly earnings results on Wednesday. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13), FiscalAI reports. The business had revenue of $13.02 million during the quarter, compared to analysts’ expectations of $13.28 million.

Aquestive Therapeutics Stock Down 2.5%

Shares of NASDAQ:AQST opened at $4.26 on Friday. The firm has a market cap of $519.72 million, a price-to-earnings ratio of -5.46 and a beta of 1.61. Aquestive Therapeutics has a 12 month low of $2.12 and a 12 month high of $7.55. The company’s fifty day simple moving average is $4.25 and its 200 day simple moving average is $5.19.

Analyst Upgrades and Downgrades

Several research firms have commented on AQST. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen downgraded Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Lake Street Capital set a $6.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, February 3rd. Finally, Piper Sandler upped their target price on Aquestive Therapeutics from $5.00 to $8.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Aquestive Therapeutics presently has an average rating of “Buy” and a consensus target price of $8.50.

Key Stories Impacting Aquestive Therapeutics

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: Management outlined a commercial push for Anaphylm (75‑rep field launch), plans to double medical affairs headcount, and reiterated a FY‑2026 revenue target of $46M–$50M — a sign the company expects meaningful commercial traction next year. Aquestive plans 75-rep Anaphylm launch and targets $46M–$50M in 2026 revenue while doubling medical affairs
• Neutral Sentiment: Company issued FY‑2026 revenue guidance of $46M–$50M (roughly in line with consensus of ~$47.4M); guidance provides a clearer model but leaves execution risk. Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Management commentary and slides from the Q4 2025 earnings call are available for details on product rollouts, margin assumptions and timing — useful for assessing execution against the new guidance. Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results missed expectations: GAAP loss per share of ($0.26) vs. consensus (~$0.13 loss) and revenue of $13.02M vs. ~$13.28M consensus — an earnings miss that likely prompted near‑term selling and raises concerns about near‑term profitability. Aquestive Therapeutics: Q4 Earnings Snapshot / MarketBeat
• Negative Sentiment: Multiple law firms have announced investor notices and investigations and a class action was filed covering securities purchased between June 16, 2025 and Jan 8, 2026 — litigation risk can increase uncertainty, potential legal costs, and investor anxiety. Investor Notice: Robbins LLP Informs Investors of the Aquestive Therapeutics, Inc. Class Action Lawsuit INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of Montreal Can lifted its position in shares of Aquestive Therapeutics by 239.6% during the 4th quarter. Bank of Montreal Can now owns 64,697 shares of the company’s stock valued at $418,000 after acquiring an additional 45,645 shares during the period. AQR Capital Management LLC lifted its holdings in Aquestive Therapeutics by 6.8% in the fourth quarter. AQR Capital Management LLC now owns 61,709 shares of the company’s stock valued at $399,000 after buying an additional 3,934 shares during the period. Corsair Capital Management L.P. acquired a new stake in Aquestive Therapeutics in the fourth quarter worth $388,000. Occudo Quantitative Strategies LP acquired a new position in Aquestive Therapeutics during the 4th quarter worth approximately $365,000. Finally, Intech Investment Management LLC lifted its holdings in shares of Aquestive Therapeutics by 58.9% in the 4th quarter. Intech Investment Management LLC now owns 33,913 shares of the company’s stock worth $219,000 after purchasing an additional 12,566 shares in the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.